Zenas Biopharma Inc (NASDAQ:ZBIO - Free Report) - Investment analysts at Wedbush raised their Q2 2025 earnings estimates for Zenas Biopharma in a research report issued to clients and investors on Thursday, May 15th. Wedbush analyst M. Fan now expects that the company will earn ($1.03) per share for the quarter, up from their prior estimate of ($1.11). Wedbush currently has a "Outperform" rating and a $35.00 price objective on the stock. Wedbush also issued estimates for Zenas Biopharma's Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.79) EPS, Q1 2026 earnings at ($1.04) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.97) EPS, FY2026 earnings at ($4.00) EPS, FY2028 earnings at ($2.35) EPS and FY2029 earnings at ($0.49) EPS.
Zenas Biopharma (NASDAQ:ZBIO - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $5.00 million.
A number of other research analysts also recently commented on ZBIO. Guggenheim restated a "buy" rating and set a $45.00 price objective on shares of Zenas Biopharma in a research note on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Zenas Biopharma in a research report on Friday, May 16th.
Check Out Our Latest Research Report on ZBIO
Zenas Biopharma Stock Performance
Shares of Zenas Biopharma stock traded up $0.57 on Monday, reaching $11.51. 35,603 shares of the company were exchanged, compared to its average volume of 182,764. The stock has a market capitalization of $481.51 million and a price-to-earnings ratio of -3.24. Zenas Biopharma has a 1-year low of $5.83 and a 1-year high of $26.25. The stock has a 50-day moving average price of $9.05.
Hedge Funds Weigh In On Zenas Biopharma
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. bought a new stake in Zenas Biopharma during the 1st quarter valued at $348,000. Nuveen LLC acquired a new position in shares of Zenas Biopharma during the first quarter valued at $250,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Zenas Biopharma during the first quarter valued at about $49,000.
Zenas Biopharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Read More
Before you consider Zenas Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas Biopharma wasn't on the list.
While Zenas Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
